Nasdaq · Healthcare
CytomX Therapeutics, Inc. (CTMX)
As-reported financials and recent SEC filings for CytomX Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$76.2M
Net income
$-17.4M
Net margin
-22.8%
Diluted EPS
—
ROE
-17.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $-22.4M | $25.0M | $-6.5M | $-101.3M | $-116.0M |
| Net income | $-17.4M | $31.9M | $-569,000 | $-99.3M | $-115.9M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-22
View on EDGAR →Largest Healthcare peers
Go deeper on CTMX
Search CytomX Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.